Testosterone replacement therapy is a medical treatment. Before discussing a gel, injection or monthly plan, establish what condition is being treated and how the diagnosis was reached.
Feeling tired or noticing a change in sex drive is a reason to discuss your health. Neither symptom, by itself, proves testosterone deficiency or tells you that TRT is the answer.
The useful starting point is a clinical explanation of symptoms, repeated laboratory findings and the underlying cause.
What replacement means
Testosterone treatment may be appropriate for men with hypogonadism after a clinician evaluates symptoms and consistently low testosterone measurements. The aim is to treat an established deficiency, not to provide a general upgrade for everyone getting older.
The Endocrine Society’s July 2026 statement reinforces accurate diagnosis. Its guideline recommends repeating a morning fasting total-testosterone measurement to confirm the finding. Our blood-test file explains why one result should not become an automatic checkout instruction.
References: Endocrine Society: diagnosis and treatment guideline / Endocrine Society: July 2026 TRT statement
The cause changes the next step
Low testosterone can arise through different problems involving the testes or the hormonal signals that regulate them. A clinician may need additional assessment to understand the cause and consider other explanations for symptoms.
Bring a full medication history, relevant diagnoses, previous results, and your priorities. Include fertility plans before discussing treatment. Testosterone can reduce sperm production; a plan for future children belongs near the start of the conversation, not after a prescription is filled.
References: Endocrine Society: diagnosis and treatment guideline / Urology Care Foundation: low testosterone
The formulation is another decision
Gels and injections differ in handling and practical risks. Approved products have specific labeling; compounded preparations do not undergo FDA approval. Ask for the exact product and why it is being proposed.
The gel-versus-injection file is about questions and tradeoffs, not a universal winner. A sales package containing several medicines does not mean every component is necessary for every patient. Each proposed medicine needs its own clinical reason.
References: DailyMed: testosterone gel 1.62% labeling / FDA: compounding questions and answers / Endocrine Society: diagnosis and treatment guideline
Treatment requires continuing decisions
Agree on what will be monitored, who reviews the results, and how benefit and harm will be reassessed. Ask how the plan changes if symptoms do not improve or a safety concern develops. Read the monitoring file before treating refills as the entire care plan.
A provider’s convenience or advertised price does not establish that treatment is appropriate. The clinic files examine public offers, while the appointment brief helps you carry the clinical questions into a real consultation.
References: Endocrine Society: diagnosis and treatment guideline / FDA: testosterone labeling changes
Source record
- Endocrine Society: diagnosis and treatment guideline
Clinical guidance for men with hypogonadism; not a self-diagnosis tool.
- Endocrine Society: July 2026 TRT statement
Current society statement emphasizing accurate diagnosis and evidence boundaries.
- Urology Care Foundation: low testosterone
Patient education on evaluation, monitoring and fertility. Current FDA update takes precedence for labeling changes.
- DailyMed: testosterone gel 1.62% labeling
Product-specific label. Does not establish safety or equivalence of every compounded formulation.
- FDA: compounding questions and answers
Compounded drugs are not FDA-approved.
- FDA: testosterone labeling changes
February 2025 update; cardiovascular boxed-warning language and blood-pressure warnings must be distinguished.
